Unknown

Dataset Information

0

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.


ABSTRACT: The acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable and heterogeneous. The strategies to overcome acquired resistance are significant. For patients with secondary T790M-positive after early generation EGFR-TKIs, osimertinib is the standard second-line therapy. In patients resistant to prior early generation EGFR-TKIs, the acquired T790M mutation overlaps with other driver gene resistance, such as HER2-and MET amplification, accounting for 4-8%. The efficacy of osimertinib is unclear in patients with concurrent multiple driver gene resistance. We here report a patient who acquired EGFR T790M, STRN-ALK fusion, and EGFR amplification after gefitinib progression and subsequent MET amplification acquired from osimertinib. The other patient acquired EGFR T790M and MET amplification post-dacomitinib and acquired CCDC6-RET fusion after osimertinib treatment. Besides, subsequent new bypass activations were the possible resistance mechanisms to second-line osimertinib. Both patients had progression-free survival (PFS) less than 4 months and limited benefits from osimertinib second-line therapy. The T790M accompanying driver gene resistance will be a new subtype after EGFR-TKIs progression, needing effective treatment options.

SUBMITTER: Zeng Y 

PROVIDER: S-EPMC9020767 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

altmetric image

Publications

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.

Zeng Yue Y   Feng Yuanqing Y   Fu Guihua G   Jiang Junlan J   Liu Xiaohan X   Pan Yue Y   Hu Chunhong C   Liu Xianling X   Wu Fang F  

Frontiers in pharmacology 20220406


The acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable and heterogeneous. The strategies to overcome acquired resistance are significant. For patients with secondary T790M-positive after early generation EGFR-TKIs, osimertinib is the standard second-line therapy. In patients resistant to prior early generation EGFR-TKIs, the acquired T790M mutation overlaps with other driver gene resistance, such as HER2-and MET amplification, accounting  ...[more]

Similar Datasets

| S-EPMC11875782 | biostudies-literature
| S-EPMC10486675 | biostudies-literature
| S-EPMC9300753 | biostudies-literature
| S-EPMC10582297 | biostudies-literature
| S-EPMC7327692 | biostudies-literature
| S-EPMC11331667 | biostudies-literature
| S-EPMC8187359 | biostudies-literature
| S-EPMC6762027 | biostudies-literature
| S-EPMC7412784 | biostudies-literature
| S-EPMC8727519 | biostudies-literature